0.2994
6.51%
+0.0183
After Hours:
.30
0.0006
+0.20%
GlycoMimetics Inc stock is currently priced at $0.2994, with a 24-hour trading volume of 2.63M.
It has seen a +6.51% increased in the last 24 hours and a -86.87% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $0.2784 pivot point. If it approaches the $0.307 resistance level, significant changes may occur.
Previous Close:
$0.2811
Open:
$0.283
24h Volume:
2.63M
Market Cap:
$5.79M
Revenue:
$1.16M
Net Income/Loss:
$-36.90M
P/E Ratio:
-0.4606
EPS:
-0.65
Net Cash Flow:
$-34.90M
1W Performance:
+12.30%
1M Performance:
-86.87%
6M Performance:
-79.35%
1Y Performance:
-85.32%
GlycoMimetics Inc Stock (GLYC) Company Profile
Name
GlycoMimetics Inc
Sector
Industry
Phone
240 243 1201
Address
9708 Medical Center Drive, Rockville, MD
GlycoMimetics Inc Stock (GLYC) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Nov-12-21 | Upgrade | Jefferies | Hold → Buy |
Nov-14-19 | Initiated | ROTH Capital | Buy |
Aug-05-19 | Downgrade | Jefferies | Buy → Hold |
Aug-05-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
Aug-05-19 | Downgrade | SunTrust | Buy → Hold |
Apr-12-19 | Initiated | Piper Jaffray | Overweight |
Dec-18-18 | Initiated | H.C. Wainwright | Buy |
Jul-26-16 | Initiated | SunTrust | Buy |
Mar-17-15 | Reiterated | Stifel | Buy |
View All
GlycoMimetics Inc Stock (GLYC) Latest News
After Golden Cross, GlycoMimetics (GLYC)'s Technical Outlook is Bright - Yahoo Movies UK
Yahoo Movies UK
GlycoMimetics Inc (GLYC) Stock: Navigating a Year of Volatility - The InvestChronicle
The InvestChronicle
Glycomimetics Q4 loss per share $0.36 - Reuters
Reuters
GlycoMimetics (NASDAQ:GLYC) Coverage Initiated by Analysts at StockNews.com - Defense World
Defense World
GlycoMimetics (NASDAQ:GLYC) Coverage Initiated by Analysts at StockNews.com - Defense World
Defense World
Healthy Upside Potential: GlycoMimetics Inc (GLYC) – Sete News - SETE News
SETE News
GlycoMimetics Inc Stock (GLYC) Financials Data
GlycoMimetics Inc (GLYC) Revenue 2024
GLYC reported a revenue (TTM) of $1.16 million for the quarter ending December 31, 2021.
GlycoMimetics Inc (GLYC) Net Income 2024
GLYC net income (TTM) was -$36.90 million for the quarter ending December 31, 2023, a +20.97% increase year-over-year.
GlycoMimetics Inc (GLYC) Cash Flow 2024
GLYC recorded a free cash flow (TTM) of -$34.90 million for the quarter ending December 31, 2023, a +25.01% increase year-over-year.
GlycoMimetics Inc (GLYC) Earnings per Share 2024
GLYC earnings per share (TTM) was -$0.58 for the quarter ending December 31, 2023, a +34.09% growth year-over-year.
About GlycoMimetics Inc
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. It also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.
Cap:
|
Volume (24h):